関連する実験動画
Updated: Apr 4, 2026

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
1.3K
メラノマ細胞の内在的なPD-1受容体の機能が腫瘍の成長を促す
Sonja Kleffel1, Christian Posch2, Steven R Barthel1
1Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Cell
|September 12, 2015
まとめ
メラノーマ細胞のプログラム細胞死1 (PD-1) は,免疫細胞がなくても腫瘍の成長を促します. この内在的なPD-1経路を阻害することで メラノーマの進行を遅らせ,新たな治療目標を示唆する.
科学分野:
- 腫瘍学
- 免疫学
- 癌 生物学
背景:
- プログラム細胞死1 (PD-1) を標的とする治療抗体は,抗腫瘍免疫を活性化することによって,メラノーマに対して有効である.
- PD-1経路の役割は,がん細胞自体,特にメラノーマでは,ほとんど未知のままです.
研究 の 目的:
- メラノーマの発症と進行におけるPD-1経路の細胞内部の機能を調査する.
- メラノーマ細胞内部のPD-1を抑制することで腫瘍の成長を抑制できるかどうかを判断する.
主な方法:
- ネズミとヒトのメラノーマ細胞亜集団におけるPD-1発現の分析.
- メラノーマ細胞内在のPD- 1をRNA干渉 (RNAi),阻害抗体,変異作用によって抑制する.
- 免疫能力,免疫低下,PD-1欠乏症を含む様々なマウスモデルにおける腫瘍の成長の評価.
- メラノーマ-PD-1の過剰発現とリガンド (PD-L1) 関与の研究
- mTORを含む下流信号経路の調査
主要な成果:
- PD - 1 を発現するがんサブポピュレーションは,ネズミおよびヒトのメラノマの両方で特定されました.
- メラノマ細胞内在のPD-1は,適応免疫とは独立して腫瘍形成を促進することが判明しました.
- メラノーマ- PD- 1の抑制は,異なる免疫能力と免疫低下モデルで腫瘍の成長を著しく抑制しました.
- メラノーマPD-1の過剰発現またはPD- L1による関与は腫瘍発生性を高めます.
- メラノーマPD-1のシグナリングは,mTORのシグナリングの調節と機械的に関連していました.
結論:
- PD-1:PD-L1軸は,メラノーマの成長において細胞内在の機能を果たしている.
- メラノーマ細胞内在のPD-1を標的とした治療は,抗PD-1治療の有効性を高める潜在的な治療戦略です.
- メラノーマ-PD-1を阻害することは,現在の免疫療法に補足して,メラノーマとの闘いに新しいアプローチを提供することができる.
関連する概念動画
Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
The Intrinsic Apoptotic Pathway
9.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
Mitogens and the Cell Cycle
8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Interactions Between Signaling Pathways
7.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Tumor Immunotherapy
2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K

